Literature DB >> 22570250

Quantitative phenotyping of inflammatory bowel disease in the IL-10-deficient mouse by use of noninvasive magnetic resonance imaging.

Svenja Michael1, Lydia M Keubler, Anna Smoczek, Martin Meier, Florian Gunzer, Christoph Pöhlmann, Udo Krause-Buchholz, Hans-J Hedrich, André Bleich.   

Abstract

BACKGROUND: Although magnetic resonance imaging (MRI) is an increasingly used diagnostic tool in the assessment of inflammatory bowel disease (IBD) in humans, diagnosis and quantitation of intestinal inflammation in animal models of IBD still depends on ex vivo techniques. The aim of this study was to evaluate whether high-field MRI is suitable for the quantitative phenotyping of gut inflammation in a dextran sulfate sodium (DSS)-triggered interleukin (IL)10-deficient (IL-10(-/-)) mouse model of IBD, especially in longitudinal studies.
METHODS: Using colitis-susceptible and -resistant backgrounds, MRI and ex vivo analyses were applied to characterize this specific model, differentiating disease severity and time-dependent alterations. Colon wall thickness, cecum wall tissue intensity, spleen, and mesenteric lymph node (MLN) volumes were evaluated 1, 2, 4, and 12 weeks after disease onset by T2-weighted MRI. Ex vivo parameters included histology, spleen, and MLN weight and analysis of cytokine expression.
RESULTS: MRI and ex vivo determined parameters correlated well, revealing a mouse strain-specific colitis development over time with characteristics typical for the DSS model in the initial and for the IL-10(-/-) model in the chronic phase. To evaluate the use of high-field MRI for monitoring therapeutic studies, mice with a profound colitis were treated with IL-10-producing Saccharomyces boulardii and monitored by MRI.
CONCLUSIONS: MRI can be utilized to quantify colitis development in the IL-10(-/-) model of IBD. Therefore, this noninvasive technique might be highly advantageous for an individual follow-up of colitis development in chronic models of IBD, facilitating the reduction of animal numbers in this kind of research.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22570250     DOI: 10.1002/ibd.23006

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  13 in total

1.  Novel insights in genetic transformation of the probiotic yeast Saccharomyces boulardii.

Authors:  Bruno Douradinha; Viviane C B Reis; Matthew B Rogers; Fernando A G Torres; Jared D Evans; Ernesto T A Marques
Journal:  Bioengineered       Date:  2013-09-05       Impact factor: 3.269

2.  In-vivo monitoring of acute DSS-Colitis using Colonoscopy, high resolution Ultrasound and bench-top Magnetic Resonance Imaging in Mice.

Authors:  J Walldorf; M Hermann; M Porzner; S Pohl; H Metz; K Mäder; A Zipprich; B Christ; T Seufferlein
Journal:  Eur Radiol       Date:  2015-05-17       Impact factor: 5.315

Review 3.  Diagnostic imaging advances in murine models of colitis.

Authors:  Markus Brückner; Philipp Lenz; Marcus M Mücke; Faekah Gohar; Peter Willeke; Dirk Domagk; Dominik Bettenworth
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

4.  Quantitatively different, yet qualitatively alike: a meta-analysis of the mouse core gut microbiome with a view towards the human gut microbiome.

Authors:  Lukasz Krych; Camilla H F Hansen; Axel K Hansen; Frans W J van den Berg; Dennis S Nielsen
Journal:  PLoS One       Date:  2013-05-01       Impact factor: 3.240

5.  Functional heterologous protein expression by genetically engineered probiotic yeast Saccharomyces boulardii.

Authors:  Lauren E Hudson; Milo B Fasken; Courtney D McDermott; Shonna M McBride; Emily G Kuiper; David B Guiliano; Anita H Corbett; Tracey J Lamb
Journal:  PLoS One       Date:  2014-11-12       Impact factor: 3.240

6.  Hypoxia ameliorates intestinal inflammation through NLRP3/mTOR downregulation and autophagy activation.

Authors:  Jesus Cosin-Roger; Simona Simmen; Hassan Melhem; Kirstin Atrott; Isabelle Frey-Wagner; Martin Hausmann; Cheryl de Vallière; Marianne R Spalinger; Patrick Spielmann; Roland H Wenger; Jonas Zeitz; Stephan R Vavricka; Gerhard Rogler; Pedro A Ruiz
Journal:  Nat Commun       Date:  2017-07-24       Impact factor: 14.919

7.  Heterologous Expression of the Leuconostoc Bacteriocin Leucocin C in Probiotic Yeast Saccharomyces boulardii.

Authors:  Ran Li; Xing Wan; Timo M Takala; Per E J Saris
Journal:  Probiotics Antimicrob Proteins       Date:  2021-02       Impact factor: 4.609

8.  Improving health from the inside: Use of engineered intestinal microorganisms as in situ cytokine delivery system.

Authors:  Christoph Pöhlmann; Mandy Thomas; Sarah Förster; Manuela Brandt; Maike Hartmann; André Bleich; Florian Gunzer
Journal:  Bioengineered       Date:  2012-10-30       Impact factor: 3.269

9.  Magnetic resonance colonography for fibrosis assessment in rats with chronic colitis.

Authors:  Chloé Melchior; Emilien Loeuillard; Rachel Marion-Letellier; Lionel Nicol; Paul Mulder; Charlène Guerin; Christine Bôle-Feysot; Moutaz Aziz; Pierre Déchelotte; Pierre Vera; Guillaume Savoye; Céline Savoye-Collet
Journal:  PLoS One       Date:  2014-07-07       Impact factor: 3.240

10.  Characterization of the Probiotic Yeast Saccharomyces boulardii in the Healthy Mucosal Immune System.

Authors:  Lauren E Hudson; Courtney D McDermott; Taryn P Stewart; William H Hudson; Daniel Rios; Milo B Fasken; Anita H Corbett; Tracey J Lamb
Journal:  PLoS One       Date:  2016-04-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.